Passage Bio, Inc. announced that on July 26, 2023, Thomas Woiwode, Ph.D., notified the company of his decision to resign from the Company?s Board of Directors (the ?Board?), including from the Compensation Committee of the Board, effective immediately. Dr. Woiwode?s decision was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices. On July 27, 2023, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the ?Governance Committee?), appointed Dr. Dolan Sondhi as a Class II director to fill a Board vacancy, and also appointed Dr. Sondhi as a member of the Governance Committee of the Board.

Dr. Sondhi is currently a Professor of Research in the Department of Genetic Medicine at Weill Cornell Medicine, having held numerous academic appointments at the college since October 1999. Additionally, Dr. Sondhi is the Associate Director at the Belfer Gene Therapy Core Facility as well as the Project Manager for Neurological Gene Therapy Projects within Weill Cornell?s Department of Genetic Medicine. Dr. Sondhi has held a variety of research roles at Weill Cornell Medicine over the last two decades, focused primarily on gene therapy, translational medicine, and the manufacturing of gene therapy products.

Prior to Weill Cornell, she completed her post-doctoral fellowship in Bioorganic Chemistry at Rockefeller University. Dr. Sondhi holds a Ph.D. in Chemistry from Brown University and a Bachelor of Science in Chemistry from St. Stephens College, Delhi University.